Phase 3 N=30 Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS
Marfan Syndrome
Primary: Central Aortic Distensibility by MRI — 3.7; 4.7; 5.7; 5.1 (mmHg ^ -1) x 10 ^ -3
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=40 Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
Marfan Syndrome
Primary: Aortic Biophysical Properties - Pulse Wave Velocity — -1.15; -0.22 change in meters/second
N/A N=71 Portico Valve-in-Valve Retrospective Registry
Aortic Valve Stenosis · Aortic Valve Failure · Aortic Insufficiency
Primary: Primary Safety Endpoint: The Rate of All-cause Mortality, Disabling Stroke, Life-threatening Bleeding Requiring Blood Transfusion, Acute Kidney Injury (AKI) Requiring…
N/A N=478 The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
Symptomatic Aortic Stenosis
Primary: Primary Safety Endpoint - Composite Safety Endpoint Based on MACCE — 25 Participants
N/A N=37 DEFLECT I: Keystone Heart Embolic Deflection Trial
Aortic Stenosis
Primary: Number of Patients Where the Device Accessed, Deployed and Was Positioned in the Aortic Arch (Device Performance) — 33 Participants
Phase 2 N=23 A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
Aortic Valve Stenosis
Primary: Changes in Aortic Valve Calcium Levels — 65; 215 Arbitrary Units — p=0.05
N/A N=20 HAART 200 Aortic Valve Annuloplasty Trial
Aortic Insufficiency
Primary: Primary Safety Outcome Measure: Survival Defined as Survival Free From All Cause Death at 6 Months Postprocedure. — 100 percentage of participants
N/A N=250 REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System
Transcatheter Aortic Valve Replacement
Primary: Primary Device Performance Endpoint: Mean Aortic Valve Pressure Gradient at 30 Days Post Implant Procedure — 11.45 mmHG
N/A N=11 REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve SystEm
Aortic Valve Stenosis · Aortic Valve Calcification · Aortic Valve Disease
Primary: Clinical Procedural Success — 9 participants
N/A N=756 Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve
Heart Valve Diseases
Primary: Incidence Rate of Adverse Events and Mortality for the Mitroflow Aortic Heart Valve Repair — 7.1; 1.27; 0.21; 0.56 Percent occurrence per patient-year
Phase 3 N=231 Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Aortic Valve Stenosis · Cardiovascular Diseases · Heart Valve Diseases
Primary: Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan — 11; 2 Participants — p=0.01
N/A N=30 Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction (BASILICA) Prospective Investigation
Native and Valve in Valve Aortic Valve Failure
Primary: Number of Participants With Procedure Success, Measured at Exit From the Catheterization Laboratory — 28 participants
N/A N=1,453 Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement
Severe Aortic Stenosis
Primary: Extreme Risk: All-cause Death or Major Stroke; High Risk Surgical: All-cause Mortality — 26.0; 39.3; 14.1; 18.9 percentage of participants, Kaplan-Meier — p=<0.0001
Phase 2 N=82 Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta
Aortic Coarctation
Primary: Study Participants With Grade 4 or 5 in Degree of Aortic Wall Injury (AWI) and/or Aortic Arch Obstruction Without Clinical Worsening — 55 participants
Phase 2 N=251 Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 54.6; 60.7 ml per square meter of body-surface area — p=0.18